ASH 2019 – Multiple Myeloma

Leslie Lauersdorf explains triplet versus quad regimens in relation to multiple myeloma. Read More ›

In patients with relapsed/refractory multiple myeloma, treatment with elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone shows encouraging responses, with manageable toxicity. Read More ›

Leslie Lauersdorf discusses key considerations for nurses and navigators surrounding the use of CAR T-cell therapy in multiple myeloma. Read More ›

Compared with intravenous (IV) administration, subcutaneous daratumumab led to similar response rates with fewer infusion-related reactions. Read More ›

Leslie Lauersdorf provides an overview of some of the most exciting clinical developments in multiple myeloma based on data presented at ASH 2019. Read More ›

In systemic amyloid light chain (AL) amyloidosis, treatment with ixazomib/dexamethasone proved more beneficial than treatment of physician’s choice, although hematologic response was not improved. Read More ›

Selinexor, pomalidomide, and dexamethasone led to high response rates in patients with multiple myeloma who were refractory to lenalidomide and had not been previously treated with pomalidomide. Read More ›

After more than 4 years of median follow-up, treatment with daratumumab, lenalidomide, and dexamethasone continues to improve progression-free survival compared with lenalidomide and dexamethasone alone in relapsed/refractory multiple myeloma, with deep and durable responses. Read More ›

Despite safety concerns related to daratumumab, a meta-analysis of 5 large randomized controlled trials showed no significant increase in treatment delays, trial discontinuation, or treatment-related deaths in patients with untreated or relapsed/refractory multiple myeloma who received the drug. Read More ›